Stryker Corp (SYK) is a renowned Fortune 500 medical technologies firm based in Kalamazoo, Michigan, USA. Since its inception in 1941 by Dr. Homer Stryker, the company has been committed to "making healthcare better". It has emerged as a global leader in the medical technology industry and provides innovative products and services in the areas of Orthopaedics, Medical and Surgical, and Neurotechnology and Spine.
Stryker's unique product portfolio is designed to help medical professionals enhance their performance, reduce healthcare costs, and most importantly, improve the lives of their patients. The company’s orthopaedics line includes joint replacements and trauma, craniomaxillofacial & thoracic products. Their medical and surgical equipment consists of surgical navigation systems, endoscopic systems, patient handling equipment, and more. Stryker's Neurotechnology and spine products include neurosurgical, neurovascular and spinal devices.
A key focus of Stryker Corp is its dedication to technological innovation, and it consistently reinvests in R&D to develop advanced medical solutions. The company’s commitment to growth is also evident in its strategic acquisitions and partnerships, as it routinely seeks to expand its reach and capabilities. Examples include their acquisition of Wright Medical Group, a global orthopaedic medical device company, and the collaboration with Microsoft to use HoloLens technology in operating rooms.
Stryker Corp’s mission and values are deeply ingrained in its operations. The company stands for integrity and puts great emphasis on its culture of accountability. The firm also takes pride in offering a diverse and inclusive work environment. They are dedicated to sustainability and believe in a "green" approach to business, which includes efforts to reduce their carbon footprint.
With a workforce of over 33,000 employees worldwide, the company generated a revenue of $14.4 billion as of 2020. Despite facing challenges amidst the COVID-19 pandemic, Stryker showcased commendable resilience and adaptability. The company continues to leverage its robust business model, a well-diversified product portfolio, and technological advancements to drive growth in the post-pandemic era.
In conclusion, Stryker Corp is a testament to the power of innovation in the medical sciences field. Their approach to healthcare solutions continues to contribute significantly to the betterment of patient health and the evolution of the global medical technology industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Independent Director Ronda Stryker recently sold US$179 million worth of Stryker Corporation (NYSE:SYK) shares, reducing her holding by 3.8%. This follows an even larger sale earlier in the year, though both transactions were at prices above the current share price of US$324. While there have been no insider purchases in the last year, Stryker maintains high insider ownership at 9.2%, valued at US$11 billion, and is experiencing earnings growth.
Stryker (SYK) stock has seen a 6.9% decline over the past year, trading near a price point ($325.73) where it bounced strongly in 2024 but has since fallen 5% on subsequent returns. While Stryker's strong operating margin and organic sales growth in MedSurg and Neurotechnology offer a plausible reason for a bounce, a slowing hip and knee business and execution risk on capital equipment sales pose a significant threat, potentially pushing the stock to the next support level at $293.30. Investors should watch for fourth-quarter organic sales growth and improvements in U.S. knee and hip sales in the upcoming January 2027 earnings report.
Enovis (NYSE:ENOV) reported strong Q3 2026 results, with sales growth on both reported and organic bases, driven by significant market share gains in its Reconstructive segment. The company also raised its full-year guidance for adjusted EBITDA and adjusted EPS, reflecting confidence in margin improvement and successful execution of its innovation-led strategy. This performance highlights Enovis's ability to capitalize on steady demand from an aging population and advancements in orthopedic medical technology.
Ronda E Stryker, a Director at Stryker (NYSE: SYK), sold 550,000 shares of the company's stock for a total of $178.92 million on November 9. The article provides an overview of Stryker's financial performance, including revenue growth, profitability metrics, and debt management, and discusses the importance of insider transactions for investors. Stryker's shares were down by 1.86% to $319.66 following the disclosure.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced the sale of its 1,000th superficial radiotherapy (SRT) system, a major commercial milestone. This achievement underscores the company's commitment to providing non-invasive treatment options for non-melanoma skin cancer and reflects increased physician awareness and dedicated reimbursement codes for SRT. Sensus Healthcare plans to continue expanding access to this technology, aiming for the next 1,000 units.
Welch & Forbes LLC has acquired a significant new stake in Stryker Corporation (NYSE:SYK), purchasing 519,163 shares valued at approximately $142.97 million during the third quarter. This acquisition makes Stryker the 14th largest position in Welch & Forbes LLC's portfolio, representing about 1.7% of its total holdings. The article also details recent insider selling activity and updated analyst price targets for Stryker.
Stryker Director Ronda Stryker sold 550,000 shares of SYK stock for approximately $178.9 million, reducing her holdings by 24.43%. This insider sale follows Stryker's recent quarterly results that missed earnings and revenue expectations, although revenue still grew 7.6% year-over-year. Despite several analysts lowering their price targets or ratings, the consensus view on the stock remains a "Moderate Buy."